Analysts Set AbbVie Inc. (NYSE:ABBV) Price Target at $267.67

AbbVie Inc. (NYSE:ABBV) has been assigned an average recommendation of “Moderate Buy” from the twenty-five brokerages that are presently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $267.6667.

ABBV has been the subject of a number of recent research reports. HSBC restated a “buy” rating and set a $300.00 price target on shares of AbbVie in a research note on Monday, July 6th. BMO Capital Markets lifted their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Canaccord Genuity Group boosted their target price on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Wells Fargo & Company raised their price target on shares of AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. Finally, Royal Bank Of Canada lifted their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $254.53 on Thursday. AbbVie has a 52-week low of $184.63 and a 52-week high of $261.64. The business’s 50 day simple moving average is $229.80 and its two-hundred day simple moving average is $221.94. The firm has a market cap of $449.70 billion, a P/E ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company posted $2.46 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities analysts forecast that AbbVie will post 14.18 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s payout ratio is 340.89%.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently modified their holdings of the business. Chelsea Counsel Co. bought a new position in AbbVie in the 3rd quarter valued at $26,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $28,000. Westend Capital Management LLC purchased a new position in shares of AbbVie in the 4th quarter worth about $29,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the period. Finally, Legacy Wealth Managment LLC ID increased its holdings in AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.